Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,060.32 +41.93 (+0.84%) Dow
38,180.50 +277.21 (+0.73%) Nasdaq
15,828.12 +222.63 (+1.43%) Bitcoin USD
59,078.29 +1,805.24 (+3.15%) CMC Crypto 200
1,274.52 +3.78 (+0.30%)
Vaxart, Inc. (VXRT)
| Previous close | 0.7006 |
| Open | 0.7182 |
| Bid | 0.7164 x 200 |
| Ask | 0.7231 x 200 |
| Day's range | 0.6900 - 0.7270 |
| 52-week range | 0.5300 - 1.5900 |
| Volume | |
| Avg. volume | 1,693,047 |
| Market cap | 125.042M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 09 Nov 2012 |
| 1y target est | N/A |
- GlobeNewswire
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate. The trial was focused on lactating mothers. Antibodies to norovirus rose on average 4.0 fold for
- GlobeNewswire
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccinationSpeaker: Dr. Sean
- GlobeNewswire
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo, effective March 18, 2024. The awards were made pursuant to the Company’s previously disclosed offer letter with Mr. Lo, and as a material inducement to his joining the Company as President and Chief Execu
